Citations

Mayo Clinic

Showing 10 of 108523 citations.

Bronchial thermoplasty: Where there is smoke, there is fire
Lim, Kaiser G. , Iyer, Vivek , Lim, Kaiser G

Allergy and Asthma Proceedings | June 23, 2015 | Volume: 36 | Issue: 4 | Pages: 251-255

10.2500/aap.2015.36.3857 | PMID 26108081 Get It

Stepping down inhaled corticosteroids from scheduled to as needed in stable asthma: Systematic review and meta-analysis
Gionfriddo, Michael R. , Hagan, John B., Hagan, Christina R., Volcheck, Gerald W., Castañeda-Guarderas, Ana, Rank, Matthew A.

Allergy and Asthma Proceedings | June 23, 2015 | Volume: 36 | Issue: 4 | Pages: 262-267

10.2500/aap.2015.36.3850 | PMID 26108083 Get It

Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
Avezum, Álvaro , Schulte, Phillip J. , Laņas, Fernando , Hanna, Michael , Pais, Prem, Erol, Çetin , Díaz, Rafael , Bartunek, Jozef, Caterina, Raffaele De , Goto, Shinya , Rużyłło, Witold , Zhu, Jun , Granger, Christopher B., Alexander, John H. , Granger, Christopher B. , Hanna, Michael G. , Lópes, Renato D. , Bahit, M Cecilia, De Caterina, Raffaele, Ruzyllo, Witold, Gersh, Bernard J. , Bahit, Maria Cecilia , Granger, Christopher B , Lanas, Fernando

Circulation | June 23, 2015 | Volume: 132 | Issue: 8 | Pages: 624-632

10.1161/circulationaha.114.014807 | PMID 26106009 Get It

Background— Apixaban is approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. However, the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial included a substantial number of patients with valvular heart disease and only excluded patients with clinically significant mitral stenosis or mechanical prosthetic heart valves. Methods and Results— We compared the effect of apixaban and warfarin on rates of stroke or systemic embolism, major bleeding, and death in patients with and without moderate or severe valvular heart disease using Cox proportional hazards modeling. Of the 18 201 patients enrolled in ARISTOTLE, 4808 (26.4%) had a history of moderate or severe valvular heart disease or previous valve surgery. Patients with valvular heart disease had higher rates of stroke or systemic embolism and bleeding than patients without valvular heart disease. There was no evidence of a differential effect of apixaban over warfarin in patients with and without valvular heart disease in reducing stroke and systemic embolism (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.51–0.97 and HR, 0.84; 95%, CI 0.67–1.04; interaction P =0.38), causing less major bleeding (HR, 0.79; 95% CI, 0.61–1.04 and HR, 0.65; 95% CI, 0.55–0.77; interaction P =0.23), and reducing mortality (HR, 1.01; 95% CI, 0.84–1.22 and HR, 0.84; 95% CI, 0.73–0.96; interaction P =0.10). Conclusions— More than a quarter of the patients in ARISTOTLE with nonvalvular atrial fibrillation had moderate or severe valvular heart disease. There was no evidence of a differential effect of apixaban over warfarin in reducing stroke or systemic embolism, causing less bleeding, and reducing death in patients with and without valvular heart disease. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00412984.
Defective Glucagon-Like Peptide 1 Secretion in Prediabetes and Type 2 Diabetes Is Influenced by Weight and Sex. Chicken, Egg, or None of the Above?
Vella, Adrian , Cobelli, Claudio

Diabetes | June 23, 2015 | Volume: 64 | Issue: 7 | Pages: 2324-2325

10.2337/db15-0292 | PMID 26106191 Get It

Upright Biplanar Slot Scanning in Pediatric Orthopedics: Applications, Advantages, and Artifacts
Hull, Nathan C. , Binkovitz, Larry A. , Schueler, Beth A. , Kolbe, Amy B. , Larson, A. Noelle , Larson, A Noelle

American Journal of Roentgenology | June 23, 2015 | Volume: 205 | Issue: 1 | Pages: W124-W132

10.2214/ajr.14.14022 | PMID 26102410 Get It

Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
Palmer, Allyson K. , Tchkonia, Tamar , LeBrasseur, Nathan K. , Chini, Eduardo N. , Xu, Ming , Kirkland, James L. , Tchkonia, Tamara, Xu, Ming , Tchkonia, T , LeBrasseur, Nathan K , Palmer, Allyson K

Diabetes | June 23, 2015 | Volume: 64 | Issue: 7 | Pages: 2289-2298

10.2337/db14-1820 | PMID 26106186 Get It

Cellular senescence is a fundamental aging mechanism that has been implicated in many age-related diseases and is a significant cause of tissue dysfunction. Accumulation of senescent cells occurs during aging and is also seen in the context of obesity and diabetes. Senescent cells may play a role in type 2 diabetes pathogenesis through direct impact on pancreatic β-cell function, senescence-associated secretory phenotype (SASP)-mediated tissue damage, and involvement in adipose tissue dysfunction. In turn, metabolic and signaling changes seen in diabetes, such as high circulating glucose, altered lipid metabolism, and growth hormone axis perturbations, can promote senescent cell formation. Thus, senescent cells might be part of a pathogenic loop in diabetes, as both a cause and consequence of metabolic changes and tissue damage. Therapeutic targeting of a basic aging mechanism such as cellular senescence may have a large impact on disease pathogenesis and could be more effective in preventing the progression of diabetes complications than currently available therapies that have limited impact on already existing tissue damage. Therefore, senescent cells and the SASP represent significant opportunities for advancement in the prevention and treatment of type 2 diabetes and its complications.
The Timing and Presentation of Major Hemorrhage After 18,947 Image-Guided Percutaneous Biopsies
Atwell, Thomas D. , Spanbauer, Jennifer C., McMenomy, Brendan P., Stockland, Andrew H., Hesley, Gina K. , Schleck, Cathy D. , Harmsen, William S. , Welch, Timothy J.

American Journal of Roentgenology | June 23, 2015 | Volume: 205 | Issue: 1 | Pages: 190-195

10.2214/ajr.14.13002 | PMID 26102398 Get It

The Impact of Subclinical Disease and Mechanism of Detection on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Olmsted County, Minnesota During 1935 Through 2012
Brito, Juan P. , Nofal, Alaa Al , Montori, Víctor M. , Hay, Ian D. , Al Nofal, Alaa, Morris, John C., Al Nofal, Alaa , Montori, Victor M , Brito, Juan P

Thyroid | June 23, 2015 | Volume: 25 | Issue: 9 | Pages: 999-1007

10.1089/thy.2014.0594 | PMID 26103159 Get It

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Hein, Alexander , Lambrechts, Diether , Minckwitz, Gϋnter von, Häberle, Lothar , Eidtmann, Holger, Tesch, Hans , Hilfrich, J., Schem, Christian , Rezai, Mahdi , Gerber, Bernd, Costa, Serban Dan, Blohmer, Jens‐Uwe , Schwedler, Kathrin, Kittel, K., Fehm, Tanja , Kunz, Georg , Beckmann, Matthias W. , Ekici, Arif B. , Hanusch, Claus , Huober, Jens , Liedtke, Cornelia, Moisse, Matthieu , Müller, Volkmar , Nekljudova, Valentina , Peuteman, Gilian, Rack, Brigitte , Rübner, Matthias, Brussel, Thomas Van , Wang, Liewei , Weinshilboum, Richard M. , Loibl, Sibylle , Fasching, Peter A. , Lambrechts, Diether , Untch, Michael , Mau, Christine , Weinshilboum, Richard M. , Lambrechts, Diether , Hein, Alexander , Lambrechts, Diether , Ekici, Arif B , Moisse, Matthieu , Fehm, Tanja

International Journal of Cancer | June 23, 2015 | Volume: 137 | Issue: 12 | Pages: 2981-2988

10.1002/ijc.29656 | PMID 26100253 Get It

Studies assessing the effect of bevacizumab (BEV) on breast cancer (BC) outcome have shown different effects on progression‐free and overall survival, suggesting that a subgroup of patients may benefit from this treatment. Unfortunately, no biomarkers exist to identify these patients. Here, we investigate whether single nucleotide polymorphisms (SNPs) in VEGF pathway genes correlate with pathological complete response (pCR) in the neoadjuvant GeparQuinto trial. HER2‐negative patients were randomized into treatment arms receiving either BEV combined with standard chemotherapy or chemotherapy alone. In a pre‐planned biomarker study, DNA was collected from 729 and 724 patients, respectively from both treatment arms, and genotyped for 125 SNPs. Logistic regression assessed interaction between individual SNPs and both treatment arms to predict pCR. Five SNPs may be associated with a better response to BEV, but none of them remained significant after correction for multiple testing. The two SNPs most strongly associated, rs833058 and rs699947, were located upstream of the VEGF‐A promoter. Odds ratios for the homozygous common, heterozygous and homozygous rare rs833058 genotypes were 2.36 (95% CI, 1.49–3.75), 1.20 (95% CI, 0.88–1.64) and 0.61 (95% CI, 0.34–1.12). Notably, some SNPs in VEGF‐A exhibited a more pronounced effect in the triple‐negative subgroup. Several SNPs in VEGF‐A may be associated with improved pCR when receiving BEV in the neoadjuvant setting. Although none of the observed effects survived correction for multiple testing, our observations are consistent with previous studies on BEV efficacy in BC. Further research is warranted to clarify the predictive value of these markers.